Related Experiment Videos
Hereditary hemorrhagic teleangiectasia--argon laser
Rhinology
|March 1, 1991
Summary
Argon laser therapy for hereditary hemorrhagic telangiectasias (HHT) was effective in 15 of 20 patients, requiring repeat treatments. Nine patients experienced significantly reduced bleeding, with four showing lasting benefits.
Area of Science:
- Vascular Medicine
- Otolaryngology
- Dermatology
Background:
- Hereditary hemorrhagic telangiectasias (HHT) is a genetic disorder causing abnormal blood vessel formation.
- Epistaxis and gastrointestinal bleeding are common symptoms of HএইচT.
- Current treatments aim to manage bleeding episodes and improve quality of life.
Purpose of the Study:
- To evaluate the efficacy and durability of argon laser therapy in patients with HHT.
- To assess the safety and patient satisfaction with the procedure.
Main Methods:
- Argon laser treatment was applied to visible telangiectasias in 20 HHT patients.
- Treatment effectiveness was assessed by the reduction in bleeding episodes.
- Patient outcomes and satisfaction were recorded.
Main Results:
- 15 out of 20 patients were initially treatable with argon laser.
- Septal perforation or persistent bleeding complicated treatment in 5 patients.
- All patients required repeat treatments due to lesion multiplicity.
- Nine patients reported favorable outcomes with minimal bleeding.
- Four patients experienced benefits lasting over one year.
Conclusions:
- Argon laser therapy is a viable treatment option for HHT, particularly for managing mucocutaneous bleeding.
- Repeat treatments are often necessary due to the widespread nature of HHT lesions.
- Long-term efficacy is achievable in a subset of patients.